Results 61 to 70 of about 4,220 (134)

ENTHEOGENS, MYSTICISM, AND NEUROSCIENCE

Zygon, 2014
Entheogens or psychedelic drugs such as lysergic acid diethylamide (LSD) and psilocybin are associated with mystical states of experience. Drug laws currently limit research, but important new work is under way at major biomedical research facilities ...
doaj   +2 more sources

Does LSD confer lasting psychological resilience? an investigation of naturalistic users experiencing job loss.

PLoS ONE
Recent studies on classic psychedelics have suggested that their use is associated with psychological strengths and resilience, thereby conferring users a type of psychological protection relative to non-users.
Benjamin A Korman
doaj   +1 more source

The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. [PDF]

Neuropsychopharmacology, 2023
Bedford P, Hauke DJ, Wang Z, Roth V, Nagy-Huber M, Holze F, Ley L, Vizeli P, Liechti ME, Borgwardt S, Müller F, Diaconescu AO.   +11 more
europepmc   +1 more source

Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans. [PDF]

Psychol Med, 2023
Kanen JW, Luo Q, Rostami Kandroodi M, Cardinal RN, Robbins TW, Nutt DJ, Carhart-Harris RL, den Ouden HEM.   +7 more
europepmc   +1 more source

The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review. [PDF]

CNS Drugs, 2023
Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre RS, Morrow JD.   +5 more
europepmc   +1 more source

Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature

Therapeutic Advances in Psychopharmacology, 2019
Background: Recognition of emotions in facial expressions (REFE) is a key aspect of social cognition. Anxiety and mood disorders are associated with deficits in REFE, and anxiolytics and antidepressants reverse these deficits.
Juliana M. Rocha, Flávia L. Osório, José Alexandre S. Crippa, José Carlos Bouso, Giordano N. Rossi, Jaime E. C. Hallak, Rafael G. dos Santos   +6 more
doaj   +1 more source

Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. [PDF]

Neuropsychopharmacology, 2023
Glazer J, Murray CH, Nusslock R, Lee R, de Wit H.   +4 more
europepmc   +1 more source

Evaluating the Potential of Microdosing 1cp‐LSD for the Treatment of Canine Anxiety: A One‐Month Case Study

Veterinary Medicine and Science
This pilot study explored the potential of microdosing 1‐cyclopropionyl‐d‐lysergic acid diethylamide (1cp‐LSD) to treat canine anxiety. A single‐case study was conducted on a 13‐year‐old female dog with severe separation anxiety, who was treated with 5 ...
Elisa Hernández‐Álvarez, Lucas F. Borkel, Jaime Rojas‐Hernández, Domingo J. Quintana‐Hernández, Ignacio García‐Serrano, Tobías Fernández‐Borkel, Manuel Zumbado, Luis Alberto Henríquez‐Hernández   +7 more
doaj   +1 more source

Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). [PDF]

J Psychopharmacol, 2022
Kopra EI, Ferris JA, Rucker JJ, McClure B, Young AH, Copeland CS, Winstock AR.   +6 more
europepmc   +1 more source

Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. [PDF]

Proc Natl Acad Sci U S A, 2021
De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, Posa L, Lopez-Canul M, He Q, Lafferty CK, Britt JP, Comai S, Aguilar-Valles A, Sonenberg N, Gobbi G.   +14 more
europepmc   +1 more source